Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow BIIB
Biogen Inc. (BIIB) Return on equity
Biogen Inc.'s return on equity over the twelve months to 30 June 2026 was 4.58%, down 2.8 percentage points from fiscal 2025 (7.39%). Over the past ten years it has ranged from 7.39% (fiscal 2025) to 44.7% (fiscal 2019) — the current reading is the lowest in ten years. That is below the Drug Manufacturers General industry median of 5.87% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 7.39% | (2.97) |
| FY2024 | 10.4% | 2.12 |
| FY2023 | 8.24% | (16.79) |
| FY2022 | 25.0% | 10.65 |
| FY2021 | 14.4% | (18.92) |
| FY2020 | 33.3% | (11.36) |
| FY2019 | 44.7% | 10.09 |
| FY2018 | 34.6% | 14.03 |
| FY2017 | 20.5% | (13.90) |
| FY2016 | 34.4% | (0.70) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. compare | 91.5% |
| NVO Novo Nordisk A/S compare | 60.8% |
| BMY Bristol Myers Squibb Company compare | 46.6% |
| GSK GSK PLC Sponsored ADR compare | 30.7% |
| AZN AstraZeneca PLC compare | 22.0% |
| SNY Sanofi compare | 5.87% |
| PFE Pfizer Inc. compare | 4.97% |
| BIIB Biogen Inc. | 4.58% |
| GILD Gilead Sciences, Inc. compare | −20.7% |
| Drug Manufacturers General industry median | 5.87% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement